Inhaled medications are the mainstay of therapy for many pediatric pulmonary diseases. Device and delivery technique selection is key to improving lung deposition of inhaled drugs. This paper will review the subject in relationship to several pediatric clinical situations: acute pediatric asthma, transnasal aerosol delivery, delivery through tracheostomies, and delivery during noninvasive and invasive mechanical ventilation. This review will focus on the pediatric age group and will not include neonates.
National Asthma Education and Prevention Program. National Heart, Lung, and Blood Institute, National Institutes of Health. Expert panel report 3: guidelines for the diagnosis and management of asthma. NIH publication No 08-4051, Bethesda, MD: National Institutes of Health; 2007. http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines. Accessed March 10, 2017.
2.
AbadessoC, NunesP, SilvestreC, MatiasE, LoureiroH, AlmeidaH. Non-invasive ventilation in acute respiratory failure in children. Pediatr Rep, 2012; 4(2):e16.
3.
ten BrinkF, DukeT, EvansJ. High-flow nasal prong oxygen therapy or nasopharyngeal continuous positive airway pressure for children with moderate-to-severe respiratory distress?. Pediatr Crit Care Med, 2013; 14(7):e326–e331.
4.
WillisLD, BerlinskiA. Survey of aerosol delivery techniques to spontaneously breathing tracheostomized children. Respir Care, 2012; 57(8):1234–1241.
5.
DiBlasiRM. Clinical controversies in aerosol therapy for infants and children. Respir Care, 2015; 60(6):894–914; discussion 914-916.
6.
't JongGW, ElandIA, SturkenboomMCJM, van den AnkerJN, StrickerBHC. Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J, 2004; 23(2):310–313.
7.
AmiravI, NewhouseMT, MinocchieriS, Castro-RodriguezJA, SchüeppKG. Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol, 2010; 125(6):1206–1211.
8.
HananiaNA, WittmanR, KestenS, ChapmanKR. Medical personnel's knowledge of and ability to use inhaling devices: metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest, 1994; 105(1):111–116.
9.
GinerJ, RouraP, HernándezC, TorrejónM, PeiróM, FernándezMJ, et al. Knowledge and attitudes of nurses in spain about inhaled therapy: results of a national survey. J Aerosol Med Pulm Drug Deliv, 2016; 29(1):86–93. doi: 10.1089/jamp.2014.1198.
10.
Castro-RodriguezJA, RodrigoGJ. Beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr, 2004; 145(2):172–177.
11.
CatesCJ, WelshEJ, RoweBH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev, 2013;(9):CD000052.
12.
SalyerJW, DiBlasiRM, CrotwellDN, CowanCA, CarterER. The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience. Respir Care, 2008; 53(3):338–345.
13.
ProAirR HFA Package Insert. Highlights of prescribing information. Horsham, Pennsylvania: Teva Respiratory; Revised June 2016.
14.
ProventilR HFA Package Insert. Prescribing information. Kenilworth, New Jersey: Schering-Plough Corporation; Revised December 2014.
15.
VentolinR HFA Package Insert. Highlights of prescribing information. Brentford, United Kingdom: GlaxoSmithKline; Revised December 2014.
16.
BerlinskiA, PenningtonD. Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics (abstract). Eur Respir J, 2016; 48(Suppl 60):A3363.
17.
ChuaHL, CollisGG, NewburyAM, ChanK, BowerGD, SlyPD, Le SouefPN. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J, 1994; 7(12):2185–2191.
MallolJ, RattrayS, WalkerG, CookD, RobertsonCF. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol, 1996; 21(5):276–281.
20.
SchüeppKG, DevadsonS, RollerC, WildhaberJH. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children. Swiss Med Wkly, 2004; 134(13-14):198–200.
21.
AmiravI, BorojeniAA, HalamishA, NewhouseMT, GolshahiL. Nasal versus oral aerosol delivery to the “lungs” in infants and toddlers. Pediatr Pulmonol, 2015; 50(3):276–283. doi: 10.1002/ppul.22999.
22.
XiJ, SiX, KimJW, BerlinskiA. Simulation of airflow and aerosol deposition in the nasal cavity of a 5-year-old child. J Aerosol Sci, 2011; 42(3):156–173.
23.
El TaoumKK, XiJ, KimJ, BerlinskiA. In-vitro evaluation of nebulized aerosols delivered via nasal route. Respir Care, 2015; 60(7):1015–1025.
24.
BerlinskiA, XiJ. Characterization of nebulized aerosols using a next generation impactor and an anatomically correct pediatric airway model. Respir Drug Deliv, 2014; 3:637–640.
25.
BerlinskiA, HaydenJB. Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. J Aerosol Med Pulm Drug Deliv, 2010; 23(6):397–404.
26.
CooperB, BerlinskiA. Albuterol delivery via facial and tracheostomy route in a model of a spontaneously breathing child. Respir Care, 2015; 60(12):1749–1758.
27.
JanssensHM, de JongsteJC, FokkensWJ, RobbenSG, WoutersK, TiddensHA. The Sophia Anatomical Infant Nose-Throat (Saint) model: a valuable tool to study aerosol deposition in infants. J Aerosol Med, 2001; 14(4):433–441.
28.
JanssensHM, De JongsteJC, HopWC, TiddensHA. Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model. Chest, 2003; 123(6):2083–2088.
29.
BhashyamAR, WolfMT, MarcinkowskiAL, SavilleA, ThomasK, CarcilloJA, CorcoranTE. Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv, 2008; 21(2):181–188.
30.
LongestPW, GolshahiL, HindleM. Improving pharmaceutical aerosol delivery during noninvasive ventilation: effects of streamlined components. Ann Biomed Eng, 2013; 41(6):1217–1232.
31.
AriA, HarwoodR, SheardM, DaileyP, FinkJB. In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr Pulmonol, 2011; 46(8):795–801.
32.
PerrySA, KesserKC, GellerDE, SelhorstDM, RendleJK, HertzogJH. Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med, 2013; 14(5):e250–e256.
33.
RéminiacF, VecellioL, Heuzé-Vourc'hN, PetitcollinA, RespaudR, CabreraM, et al. Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv, 2016; 29(2):134–141.
34.
RéminiacF, VecellioL, LoughlinRM, Le PennecD, CabreraM, Vourc'hNH, et al. Nasal high flow nebulization in infants and toddlers: An in vitro and in vivo scintigraphic study. Pediatr Pulmonol, 2017; 52(3):337–344.
35.
O'BrienKC, NewthCJL, LeungK, CoatesA. Epinephrine delivery using a humidified high flow oxygen delivery system (abstract). Am J Respir Crit Care Med, 2007; 175:A195.
36.
LeungK, NewthCJ, HotzJC, O'BrienKC, FinkJB, CoatesAL. Delivery of epinephrine in the vapor phase for the treatment of croup. Pediatr Crit Care Med, 2016; 17(4):e177–e181.
37.
FarneyKD, KuehneBT, GibsonLA, NelinLD, ShepherdEG. In vitro evaluation of radio-labeled aerosol delivery via a variable-flow infant CPAP system. Respir Care, 2014; 59(3):340–344.
38.
BoucherP, BoucherR, ButtonBM, JohnsonMR, FinkJB, HickeyAJ, et al. Aerosol delivery systems, compositions and methods. United States Patent 20140109899 A1. http://www.google.com/patents/US20140109899. Accessed March 10, 2017.
39.
MorganSE, MosakowskiS, SolanoP, HallJB, TungA. High-flow nasal cannula and aerosolized β agonists for rescue therapy in children with bronchiolitis: a case series. Respir Care, 2015; 60(9):e161–e165.
40.
LongestPW, GolshahiL, BeharaSR, TianG, FarkasDR, HindleM. Efficient nose-to-lung (N2L) aerosol delivery with a dry powder inhaler. J Aerosol Med Pulm Drug Deliv, 2015; 28(3):189–201.
41.
GolshahiL, TianG, AzimiM, SonYJ, WalengaR, LongestPW, HindleM. The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy. Pharm Res, 2013; 30(11):2917–2930.
42.
TrachselD, HammerJ. Indications for tracheostomy in children. Paediatr Respir Rev, 2006; 7(3):162–168.
43.
BaranD, DachyA, KlasterskyJ. Concentration of gentamicin in bronchial secretions of children with cystic fibrosis of tracheostomy (Comparison between the intramuscular route, the endotracheal instillation and aerosolization). Int J Clin Pharmacol Biopharm, 1975; 12(3):336–341.
44.
LewisJF, McCaigL. Aerosolized versus instilled exogenous surfactant in a nonuniform pattern of lung injury. Am Rev Respir Dis, 1993; 148(5):1187–1193.
45.
BerlinskiA, ChavezA. Albuterol delivery via metered dose inhaler in a spontaneously breathing pediatric tracheostomy model. Pediatr Pulmonol, 2013; 48(10):1026–1034.
46.
BerlinskiA. Nebulized albuterol delivery in a model of spontaneously breathing children with tracheostomy. Respir Care, 2013; 58(12):2076–2086.
47.
AlhamadBR, FinkJB, HarwoodRJ, SheardMM, AriA. Effect of aerosol devices and administration techniques on drug delivery in a simulated spontaneously breathing pediatric tracheostomy model. Respir Care, 2015; 60(7):1026–1032.
48.
BerlinskiA, CooperB. Oronasal and tracheostomy delivery of soft mist and pressurized metered-dose inhalers with valved holding chamber. Respir Care, 2016; 61(7):913–919.
49.
PiccuitoCM, HessDR. Albuterol delivery via tracheostomy tube. Respir Care, 2005; 50(8):1071–1076.
50.
AmiravI, NewhouseMT. Aerosol therapy in tracheotomized children: time for guidelines!. Respir Care, 2012; 57(8):1350.
51.
ShermanJM, DavisS, Albamonte-PetrickS, ChatburnRL, FittonC, GreenC, et al. Care of the child with a chronic tracheostomy. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med, 2000; 161(1):297–308.
52.
AriA, HarwoodRJ, SheardMM, FinkJB. An in vitro evaluation of aerosol delivery through tracheostomy and endotracheal tubes using different interfaces. Respir Care, 2012; 57(7):1066–1070.
53.
LaznerMR, BasuAP, KloninH. Non-invasive ventilation for severe bronchiolitis: analysis and evidence. Pediatr Pulmonol, 2012; 47(9):909–916.
54.
AmaddeoA, MoreauJ, FrapinA, KhiraniS, FelixO, Fernandez-BolanosM, et al. Long term continuous positive airway pressure (CPAP) and noninvasive ventilation (NIV) in children: initiation criteria in real life. Pediatr Pulmonol, 2016; 51(9):968–974.
55.
BerlinskiA. Inhaled drug delivery for children on long-term mechanical ventilation. In: SterniLM, CarrollJL. Caring for the ventilator dependent child: a clinical guide, 1st edition. New York: Humana Press; 2016:217–239.
56.
BrodieT, AdalatS. Unilateral fixed dilated pupil in a well child. Arch Dis Child, 2006; 91(12):961.
57.
SimondsAK, HanakA, ChatwinM, MorrellM, HallA, ParkerKH, et al. Evaluation of droplet dispersion during noninvasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess, 2010; 14(46):131–172.
58.
FaurouxB, IttiE, PigeotJ, IsabeyD, MeignanM, FerryG, et al. Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study. Am J Respir Crit Care Med, 2000; 162(6):2265–2271.
59.
WhiteCC, CrotwellDN, ShenS, SalyerJ, YungD, ZhengJ, DiBlasiRM. Bronchodilator delivery during simulated pediatric noninvasive ventilation. Respir Care, 2013; 58(9):1459–1466.
60.
VelascoJ, BerlinskiA. Aerosol delivery in a pediatric model of non-invasive ventilation (abstract). Am J Respir Crit Care Med, 2016; A2201.
61.
DaiB, KangJ, SunLF, TanW, ZhaoHW. Influence of exhalation valve and nebulizer position on albuterol delivery during noninvasive positive pressure ventilation. J Aerosol Med Pulm Drug Deliv, 2014; 27(2):125–132.
62.
BranconnierMP, HessDR. Albuterol delivery during noninvasive ventilation. Respir Care, 2005; 50(12):1649–1653.
63.
LinHL, HarwoodRJ, FinkJB, GoodfellowLT, AriA. In vitro comparison of aerosol delivery using different face masks and flow rates with a high-flow humidity system. Respir Care, 2015; 60(9):1215–1219.
64.
AriA, FinkJB, DhandR. Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv, 2012; 25(6):319–332.
65.
GarnerSS, WiestDB, BradleyJW, HabibDM. Two administration methods for inhaled salbutamol in intubated patients. Arch Dis Child, 2002; 87(1):49–53.
66.
FerrariF, LiuZH, LuQ, BecqueminMH, LouchahiK, AymardG, et al. Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med, 2008; 34(9):1718–1723.
67.
BerlinskiA, HoltS, ThurmanT, HeulittM. Albuterol delivery during mechanical ventilation in an ex-vivo porcine model. J Aerosol Med Pulm Drug Deliv, 2013; 26(2):A57.
68.
GarnerSS, WiestDB, BradleyJW. Albuterol delivery by metered-dose inhaler with a pediatric mechanical ventilatory circuit model. Pharmacotherapy, 1994; 14(2):210–214.
69.
WildhaberJH, HaydenMJ, DoreND, DevadasonSG, LeSouëfPN. Salbutamol delivery from a hydrofluoroalkane pressurized metered-dose inhaler in pediatric ventilator circuits: an in vitro study. Chest, 1998; 113(1):186–191.
70.
BerlinskiA, WaldrepJC. Metering performance of several metered-dose inhalers with different spacers/holding chambers. J Aerosol Med, 2001; 14(4):427–432.
71.
DiotP, MorraL, SmaldoneGC. Albuterol delivery in a model of mechanical ventilation. Comparison of metered-dose inhaler and nebulizer efficiency. Am J Respir Crit Care Med, 1995; 152(4 Pt 1):1391–1394.
72.
GarnerSS, WiestDB, BradleyJW. Albuterol delivery by metered-dose inhaler in mechanically ventilated pediatric lung model. Crit Care Med, 1996; 24(5):870–874.
73.
HabibDM, GarnerSS, BrandeburgS. Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model. Pharmacotherapy, 1999; 19(2):143–149.
74.
GarnerSS, WiestDB, StevensCE, HabibDM. Effect of heliox on albuterol delivery by metered-dose inhaler in pediatric in vitro models of mechanical ventilation. Pharmacotherapy, 2006; 26(10):1396–1402.
75.
MitchellJP, NagelMW, WiersemaKJ, DoyleCC, MigounovVA. The delivery of chlorofluorocarbon-propelled versus hydrofluoroalkane-propelled beclomethasone dipropionate aerosol to the mechanically ventilated patient: a laboratory study. Respir Care, 2003; 48(11):1025–1032.
76.
MouloudiE, KatsanoulasK, AnastasakiM, AskitopoulouE, GeorgopoulosD. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of end-inspiratory pause. Eur Respir J, 1998; 12(1):165–169.
77.
MouloudiE, PrinianakisG, KondiliE, GeorgopoulosD. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of flow pattern. Eur Respir J, 2000; 16(2):263–268.
78.
HanhanU, KissoonN, PayneM, TaylorC, MurphyS, DeNicolaLK. Effects of in-line nebulization on preset ventilator variables. Respir Care, 1993; 38(5):474–478.
79.
McPeckM, O'RiordanTG, SmaldoneGC. Choice of mechanical ventilator: influence on nebulizer performance. Respir Care, 1993; 38(8):887–895.
80.
AriA, AreabiH, FinkJB. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir Care, 2010; 55(7):837–844.
81.
Di PaoloER, PannatierA, CottingJ. In vitro evaluation of bronchodilator drug delivery by jet nebulization during pediatric mechanical ventilation. Pediatr Crit Care Med, 2005; 6(4):462–469.
82.
AriA, AtalayOT, HarwoodR, SheardMM, AljamhanEA, FinkJB. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care, 2010; 55(7):845–851.
83.
BerlinskiA, WillisJR. Albuterol delivery via intrapulmonary percussive ventilator and jet nebulizer in a pediatric ventilator model. Respir Care, 2010; 55(12):1699–1704.
84.
BerlinskiA, WillisJR. Albuterol delivery by 4 different nebulizers placed in 4 different positions in a pediatric ventilator in vitro model. Respir Care, 2013; 58(7):1124–1133.
85.
Sidler-MoixAL, DolciU, Berger-GryllakiM, PannatierA, CottingJ, Di PaoloER. Albuterol delivery in an in vitro pediatric ventilator lung model: comparison of jet, ultrasonic, and mesh nebulizers. Pediatr Crit Care Med, 2013; 14(2):e98–e102.
86.
WanGH, LinHL, FinkJB, ChenYH, WangWJ, ChiuYC, et al. In vitro evaluation of aerosol delivery by different nebulization modes in pediatric and adult mechanical ventilators. Respir Care, 2014; 59(10):1494–500.
87.
BerlinskiA, WillisJR. Effect of tidal volume and nebulizer type and position on albuterol delivery in a pediatric model of mechanical ventilation. Respir Care, 2015; 60(10):1424–1430.
88.
AhrensRC, RiesRA, PopendorfW, WieseJA. The delivery of therapeutic aerosols through endotracheal tubes. Pediatr Pulmonol, 1986; 2(1):19–26.
89.
BerlinskiA, KumaranS. Particle size characterization of nebulized albuterol delivered by a vibrating mesh nebulizer through pediatric endotracheal tubes (abstract). Am J Respir Crit Care Med, 2016; A2191.
90.
FangTP, LinHL, ChiuSH, WangSH, DiBlasiRM, TsaiYH, FinkJB. Aerosol delivery using jet nebulizer and vibrating mesh nebulizer during high frequency oscillatory ventilation: an in vitro comparison. J Aerosol Med Pulm Drug Deliv, 2016; 29(5):447–453.
91.
LongestPW, TianG. Development of a new technique for the efficient delivery of aerosolized medications to infants on mechanical ventilation. Pharm Res, 2015; 32(1):321–336.
92.
BerlinskiA, WillisJR. Albuterol delivery by 4 different nebulizers placed in 4 different positions in a pediatric ventilator in vitro model. Respir Care, 2013; 58(7):1124–1133.
